Literature DB >> 25941328

De novo-developed antibodies to donor MHC antigens lead to dysregulation of microRNAs and induction of MHC class II.

Zhongping Xu1, Deepak K Nayak1, Nicholas Benshoff1, Ramsey Hachem2, Andrew E Gelman1, Thalachallour Mohanakumar3.   

Abstract

Immune responses to HLA and development of anti-donor HLA (DSA) were shown to play a role in chronic rejection following transplantation. We hypothesized that Abs to MHC change microRNAs (miRNAs), leading to chronic lung allograft rejection. Microarray analysis was performed in a murine model of anti-MHC-induced obliterative airway disease (OAD), a correlate of obliterative bronchiolitis. A unique profile of dysregulated miRNAs was detected in OAD mice on days 7 and 15 after Ab administration compared with control. Sixty-seven miRNAs were increased and 42 miRNAs were decreased in OAD mice on day 7. In addition, 15 miRNAs were overexpressed and 16 miRNAs were underexpressed in OAD mice on day 15. The expression of miR-16 and miR-195 was significantly decreased in lungs of OAD mice, as assessed by quantitative RT-PCR and in situ hybridization, with increases in H-2 Aa and H-2 Dma mRNA levels. Significant reductions in miR-16 and miR-195 levels were also noted in lung transplant (LTx) patients with DSA compared with LTx patients without DSA. Bioinformatic TargetScan and reporter assays identified the binding of miR-16 and miR-195 to the 3'-untranslated region of regulatory factor X 5. Quantitative PCR and immunohistochemistry indicated posttranscriptional increases in regulatory factor X 5 mRNA and protein expression in OAD mice, as well as in LTx recipients with DSA, which was associated with increased expression of HLA-DPA1, HLA-DQA1, and HLA-DRA mRNA. Therefore, our results demonstrated that miRNAs induced by alloimmunity may play important roles in chronic rejection after LTx.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25941328      PMCID: PMC4458403          DOI: 10.4049/jimmunol.1401848

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  53 in total

1.  Temporal relationship between the development of anti-HLA antibodies and the development of bronchiolitis obliterans syndrome after lung transplantation.

Authors:  A Jaramillo; M A Smith; D Phelan; S Sundaresan; E Trulock; J Lynch; J Cooper; G A Patterson; T Mohanakumar
Journal:  Transplant Proc       Date:  1999 Feb-Mar       Impact factor: 1.066

2.  A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients.

Authors:  K Masternak; E Barras; M Zufferey; B Conrad; G Corthals; R Aebersold; J C Sanchez; D F Hochstrasser; B Mach; W Reith
Journal:  Nat Genet       Date:  1998-11       Impact factor: 38.330

3.  Expression of cell-specific markers for alveolar epithelium in fetal rat lung.

Authors:  M C Williams; L G Dobbs
Journal:  Am J Respir Cell Mol Biol       Date:  1990-06       Impact factor: 6.914

4.  Analysis of the defect in IFN-gamma induction of MHC class II genes in G1B cells: identification of a novel and functionally critical leucine-rich motif (62-LYLYLQL-68) in the regulatory factor X 5 transcription factor.

Authors:  W J Brickey; K L Wright; X S Zhu; J P Ting
Journal:  J Immunol       Date:  1999-12-15       Impact factor: 5.422

Review 5.  Bronchiolitis obliterans syndrome: pathogenesis and management.

Authors:  Ramsey R Hachem; Elbert P Trulock
Journal:  Semin Thorac Cardiovasc Surg       Date:  2004

6.  Human leucocyte antigen-identical haematopoietic stem cell transplantation in major histocompatiblity complex class II immunodeficiency: reduced survival correlates with an increased incidence of acute graft-versus-host disease and pre-existing viral infections.

Authors:  Raffaele Renella; Capucine Picard; Bénédicte Neven; Marie Ouachée-Chardin; Jean-Laurent Casanova; Françoise Le Deist; Marina Cavazzana-Calvo; Stéphane Blanche; Alain Fischer
Journal:  Br J Haematol       Date:  2006-09       Impact factor: 6.998

7.  HLA-A locus mismatches and development of antibodies to HLA after lung transplantation correlate with the development of bronchiolitis obliterans syndrome.

Authors:  S Sundaresan; T Mohanakumar; M A Smith; E P Trulock; J Lynch; D Phelan; J D Cooper; G A Patterson
Journal:  Transplantation       Date:  1998-03-15       Impact factor: 4.939

Review 8.  Post-transplant bronchiolitis obliterans.

Authors:  A Boehler; M Estenne
Journal:  Eur Respir J       Date:  2003-12       Impact factor: 16.671

9.  Effect of development of antibodies to HLA and cytomegalovirus mismatch on lung transplantation survival and development of bronchiolitis obliterans syndrome.

Authors:  M A Smith; S Sundaresan; T Mohanakumar; E P Trulock; J P Lynch; D L Phelan; J D Cooper; G A Patterson
Journal:  J Thorac Cardiovasc Surg       Date:  1998-11       Impact factor: 5.209

10.  A functionally essential domain of RFX5 mediates activation of major histocompatibility complex class II promoters by promoting cooperative binding between RFX and NF-Y.

Authors:  J Villard; M Peretti; K Masternak; E Barras; G Caretti; R Mantovani; W Reith
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

View more
  5 in total

1.  Regulation of Endothelial-to-Mesenchymal Transition by MicroRNAs in Chronic Allograft Dysfunction.

Authors:  Emily K Glover; Nina Jordan; Neil S Sheerin; Simi Ali
Journal:  Transplantation       Date:  2019-04       Impact factor: 4.939

2.  Role of Circulating MicroRNAs in the Immunopathogenesis of Rejection After Pediatric Lung Transplantation.

Authors:  Zhongping Xu; Wei Yang; Nancy Steward; Stuart C Sweet; Lara Danziger-Isakov; Peter S Heeger; Thalachallour Mohanakumar
Journal:  Transplantation       Date:  2017-10       Impact factor: 4.939

Review 3.  The importance of non-HLA antibodies in transplantation.

Authors:  Qiuheng Zhang; Elaine F Reed
Journal:  Nat Rev Nephrol       Date:  2016-06-27       Impact factor: 28.314

Review 4.  The Potential of MicroRNAs as Novel Biomarkers for Transplant Rejection.

Authors:  Matthias Hamdorf; Satoru Kawakita; Matthew Everly
Journal:  J Immunol Res       Date:  2017-01-16       Impact factor: 4.818

Review 5.  Antibody-mediated rejection after lung transplantation.

Authors:  Amit I Bery; Ramsey R Hachem
Journal:  Ann Transl Med       Date:  2020-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.